Sandbox Reserved 1777

This Sandbox is Reserved from February 27 through August 31, 2023 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1765 through Sandbox Reserved 1795.

To get started: Click the edit this page tab at the top. Save the page after each step, then edit it again. show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page. Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc. More help: Help:Editing

spinqualitylabelsall models SHOC2-PP1C-MRAS (PDB entry 7upi) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Introduction Figure 1. Schematic representation of RAS/RAF/MEK/ERK pathway after assembly of SHOC2-PP1C-MRAS complex. SHOC2-PP1C-MRAS is a regulatory protein and enzyme complex that is involved in regulating cell proliferation and division . This complex regulates the vast RAS-MAPK signaling pathway through control of the initial RAF MAPKKK. This pathway is initially activated by the binding of a growth factor to a GTPase which initiates intracellular RAS activation, such as HRAS, NRAS, or KRAS. [1]. RAS-GTPases are a family of monomeric G-proteins that function as molecular switches and are key in regulatory parts in signaling cascades. The RAS molecular switch involves alternating between binding GTP for the active state and GDP to become inactive . After activation via an extracellular growth factor, the RAS-GTPase enzyme binds GTP, FIGURE OUT WHAT HAPPENS HERE RAF by phosphorylating the serine 259 residue. Activated RAF phosphorylates a series of downstream kinases including MEK and ERK. The RAS/RAF/MEK/ERK pathway is a critical signaling cascade for activating transcription factors and regulating gene expression. Structure Overview The protein combines 3 separate (see notes for more). SHOC2, PP1C, and MRAS, to form the active protein (SMP complex), as seen in Figure 2. The SMP complex was determined via cryo-electron microscopy as well as x-ray diffraction. The overall structure has PP1C and MRAS bound within the concave surface of SHOC2, leaving the catalytic site of PP1C and the GTP binding cleft in MRAS exposed. SHOC2 Figure 2. Surface representation of SHOC2-PP1C-MRAS (PDB 7upi). SHOC2 (blue), PP1C (orange) and MRAS (green). SHOC2 is a scaffolding protein which acts as a cradle to bind PP1C and MRAS (REF), serving as an aggregation point for these 3 signaling proteins. SHOC2 is a leucine rich repeat (LRR) protein consisting of 20 consecutive LRR motifs. LRR motifs form an an extended β sheet on the inner concave surface of SHOC2 with alpha helices facing outward, which help bind the whole protein. These LRR motifs result in a largely hydrophobic core within the concaved region.. PP1C PP1C is the catalytic domain of the phosphatase enzyme PP1, which removes reversible phosphorylations from signaling proteins. PP1C is a serine/threonine phosphatase that is involved in cellular signaling pathways that control cell growth, division, and metabolism (REF) and explain more, see notes. MRAS MRAS is a monomeric GTPase and is anchored in the cell membrane. When MRAS binds GTP, it becomes active, and the rest can only bind when this is activated. MRAS is a subvariant of the RAS protein and therefore shares most of it's regulatory and effector interactions. While other RAS variants bind in complex with SHOC2 and PP1 to allow it to have phosphatase activity, MRAS binds the tightest. Switch I and II A key feature in allowing MRAS to be in its active vs inactive state is MRAS' switches. When MRAS is active GTP is bound and the switches allow MRAS to be bound with PP1C. When MRAS is inactive GDP is bound and the switches do not allow MRAS to bind to PP1C. The switches determine whether MRAS can bind to SHOC2-PP1C. The switches have to go through a conformational change to allow binding of SHOC2-PP1C to MRAS. The conformational change is needed because without it SHOC2-PP1C could bind to MRAS when MRAS is still inactive. This process would cause the SHOC2-PP1C-MRAS pathway to constantly be running. The switches and GDP/GTP help regulate this process. This conformational change is caused by GTP replacing GDP. When GTP is bound, MRAS shifts and binds with the previously associated SHOC2-PP1C complex. When GDP is bound, switch II in MRAS is moved outward, which causes a steric clash with SHOC2 (Switch I and II with GDP). When GTP is bound, switch II in MRAS can form various hydrogen bonding, pi stacking and hydrophobic interactions with SHOC2 (Switch I and II with GTP). When MRAS is bound to SHOC2-PP1C, switch I has an important role in making interactions with PP1C. Stabilizing Interactions in Ternary Complex MRAS binds to SHOC2 exclusively through its concave LRRs, primarily by the descending loop and strands of LRR domains 2-10. PP1C binds with the ascending loops of the SHOC2 LRR regions, and is further engaged through the N-terminal region of SHOC2 containing the RVxF motif . The initial forming of the complex begins with SHOC2-PP1C engagement, then is completed and stabilized by the GTP-loaded MRAS binding (apparently described differently elsewhere?) . Once associated with SHOC2, MRAS binds to PP1C. Binding to MRAS localizes the other two proteins to the RAS signaling regions of the membrane to begin cellular signaling. Active Site Once all the domains are bound NTpS binds to PP1C in the active site. Once NTpS is bound it becomes dephosphorylated and the complex falls apart. NTpS is dephosphorylated to prevent the active dimeric RAF from inactivating and changing into its monomeric structure. The NTpS active site is surrounded by hydrophobic and acidic regions along with the C-terminus. These regions are located on the surface of PP1C whereas the active site is placed further into the structure. It is thought that these regions help the ligand bind to the active site by making interactions that will lead NTpS into the protein. There is still some uncertainty as to how the substrate selectivity works but these regions could play an essential role in it. Specifically, the pS from NTpS would bind to the hydrophobic region on PP1C. NTpS can bind to the PP1C active site without PP1C also being bound to SHOC2 and MRAS, however the catalytic activity is much slower and the reaction is less efficient. Also for this event to occur NTpS would need to be exposed from its binding site in the inactive RAF complex. A RAS has to bind to RAF to expose the NTpS allowing PP1C and NTpS to bind. Activation of RAF Figure 3. Schematic representation of RAF activation. Once the SMP complex comes together, it plays a key role in regulating the activation of the RAF and MAPK pathway. To do so, PP1C, enhanced through the interactions with SHOC2 and MRAS, phosphorylates serine 259 on RAF kinases. Doing so regulates cell growth, survival, proliferation, and differentiation . Implications The SHOC2-MRAS-PP1C complex's key role in the regulation of the MAPK-RAF pathway means that minor changes in its structure or function can have drastic biological consequences. Unregulated activation of the MAPK pathway is the cause of several human cancers due to unchecked cell division and proliferation. Mutations that stabilize the interactions of the SMP complex enhances PP1C phosphatase activity , leading to increased RAF signaling and accelerated cell division. Most SHOC2 or PP1C mutations alter residues that are the direct contact points, stabilizing the interaction between the two proteins. Mutations to MRAS lead to persistent loading of GTP, leading to consistent activation of the cell signaling pathway. The unregulated MAPK pathway is also responsible for a multitude of developmental disorders commonly known as RASopathies . One such RASopathy caused by the mutation of a RAF kinase is known as Noonan Syndrome (NS), which enhances complex formation by stabilizing the interactions of each member. NS is a genetic disorder that can prevent normal development during the neonatal period, leading to difficulties with feeding and a failure to thrive. The characteristic features of NS become more obvious in infancy and childhood. NS patients often have unusual facial characteristics, short stature, a variety of heart defects and disease, and other physical problems and developmental delays.